HOLD PM at sub-benchmark weight with mandatory 20-25% trim on $194-200 relief rally; re-engage at $172-178 support or >$200.17 breakout
HOLD PM at sub-benchmark weight is the correct decision because it satisfies both the 8/21 lesson (no Underweight initiation when bearish momentum coexists with intact long-term floor and constructive volume profile, which cost +1.7%/+2.0% alpha in back-test) and the 8/26 lesson (mandatory trim when upper Bollinger + sub-average volume + negative 30-day return all trigger simultaneously at $191). The 20-25% trim size is calibrated for the 2-5% near-term price gap to the $194-200 trim zone at $191 entry (smaller than the $194 entry that warranted 50% in 8/26 reflection). Risk/reward asymmetry of ~0.6:1 (bull case +4-7% to $200-204 vs bear case -10 to -14% to $165-175) justifies trimming but not Underweight, as the $165-175 bear target requires macro shock or thesis break that $9.7B FCF, 40% operating margins, and rising 200 SMA at $170-172 structurally resist. The highest-value component is the catalyst sequencing rule: no fresh capital adds within 6 weeks of Q3'26 earnings on a stretched-multiple defensive name. Upgrade to Overweight requires confirmed weekly close >$200.17 on >5M volume with positive MACD, Q3'26 earnings confirming >40% smoke-free mix with margin expansion and EPS >$1.95, or ZYN U.S. market share >40%; downgrade to Underweight requires confirmed weekly close below $170 on volume, Q3'26 EPS below $1.85 with deteriorating smoke-free mix, Brazil adverse ruling >$2B, or ZYN regulatory tightening.
| Position | Action |
|---|---|
| Relief rally into $194-200 zone (upper Bollinger rejection, prior failed breakout overhead supply) | Trim 20-25% of position |
| Confirmed weekly close below $186.67 (50 SMA) with expanding volume | Trim additional 10% of position |
PM is a compelling long at $191.89 because the smoke-free transformation is not priced in—the ZYN ULTRA FDA authorization provides a fresh regulatory catalyst, Q2'26 revenue is accelerating at +10.4% YoY, and the stock trades at a discount to intrinsic value with best-in-class cash generation and a 4.7%+ historical dividend yield.
| Indicator | Value | Signal |
|---|---|---|
| 200 SMA | $171.70 | bullish |
| 50 SMA | $186.95 | bullish |
| 10 EMA | $190.96 | bullish |
| RSI (14) | 53.82 | neutral |
| MACD | 1.22 | bullish |
| MACD Signal | 1.02 | bullish |
| MACD Histogram | +0.19 | bullish |
| Bollinger Upper Band | $194.36 | neutral |
| Bollinger Middle Band (20 SMA) | $189.11 | neutral |
| Bollinger Lower Band | $183.86 | neutral |
| ATR (14) |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed weekly close above $200.17 on volume >5M shares with positive MACD histogram
Then: Re-enter/layer into position
Forward valuation shows a margin of safety, not stretched multiples
↩ rebuts: “Bear points to PE 26.4x TTM as evidence of stretched multiples”
EV: ~8% upside to $203.80 fair value; ~10-12% capital appreciation + ~5% dividend yield = ~15-17% total return · concedes: YTD return of 17% means some upside may be already realized; 30-day momentum is negative at -3.12%; Combustible volumes continue to decline globally
PM at $191 is a fully-priced, over-owned consumer defensive with stale catalysts, declining EPS momentum, and asymmetric downside risk that makes the current risk/reward actively negative.
EV: $165-$175 (50% retracement of July rally + 200 SMA test) · concedes: Smoke-free transformation thesis isn't wrong—it's already in the price; Mid-single-digit smoke-free volume growth is meaningful; ZYN does lead the nicotine pouch category; Dividend has been reliable historically; Beta of 0.40 provides some defensive characteristics
→ vs conservative: Cherry-picks single quarter ($1.80 vs $1.95 YoY) while ignoring multi-quarter uptrend; PEG 2.52 dismissed as failing to capture transformation catalysts; 'near 52-week high' is fear-based, not data-driven; dividend yield comparison ignores growing nature of PM dividend vs fixed Treasury coupons; technical bearish indicators cherry-picked while ignoring the same report's HOLD with bullish bias conclusion
→ vs neutral: Technical distribution narrative (failed Bollinger tests, declining volume, MACD histogram 95% weaker) contradicts the same report's overall bullish structure; risk/reward of 0.6:1 assumes unwarranted collapse without fundamental catalyst
| $4.53 |
| neutral |
| Rating/Verdict | HOLD (Bullish Bias) | neutral |
Support: 171.7 · 186.95 · 183.86 · 182.83 | Resistance: 190.96 · 194.36 · 196.66 · 200.17
PM exhibits a textbook bullish moving average stack (Price $191.89 > 10 EMA $190.96 > 50 SMA $186.95 > 200 SMA $171.70) confirming intact structural uptrend. Short-term momentum is neutral-to-mildly bullish: RSI at 53.82 sits near the 50 midline with no bearish divergence, MACD has recrossed above zero and its histogram just flipped positive around 08-25 after a mid-August washout (low -1.16). Volatility is contracting (ATR declined ~24% from July peak of $5.94 to $4.53), consistent with a basing/consolidation phase. Near-term resistance is the Bollinger Upper Band at $194.36 (tested multiple times but not decisively broken), with the July swing high at $200.17 as the next target. Key support is the 50 SMA at $186.95, with a 2×ATR stop level near $182.83 defining the bearish invalidation zone. Volume has declined alongside volatility, reinforcing the choppy, range-bound tape. HOLD with bullish bias; patient holders should remain positioned with new entries scaled on either a retest of $186.95 or a confirmed breakout above $194.36 on volume >4M shares.
Market Cap
$299.08 B
PE Ratio (TTM)
26.36x
Forward PE
20.93x
EPS (TTM)
$7.28
Forward EPS
$9.17
Dividend Yield
3.09%
Beta
0.40
Price/Book
-34.84x
PEG Ratio
2.52
52-Week High
$207.76
52-Week Low
$142.11
50-Day Avg
$186.82
200-Day Avg
$173.44
Net Revenue FY2025
$40,648 M
Net Revenue FY2024
$37,878 M
Net Revenue FY2023
$35,174 M
Net Revenue FY2022
$31,762 M
Gross Profit FY2025
$27,282 M
EBITDA FY2025
$17,504 M
EBIT FY2025
$15,467 M
Operating Income FY2025
$14,892 M
Net Income FY2025
$11,348 M
Diluted EPS FY2025
$7.26
Operating Margin FY2025
36.6%
Net Income FY2024
$7,057 M
Diluted EPS FY2024
$4.53
Operating Margin FY2024
35.4%
Net Income FY2023
$7,813 M
Diluted EPS FY2023
$5.02
Operating Margin FY2023
32.8%
Net Income FY2022
$9,048 M
Diluted EPS FY2022
$5.81
Operating Margin FY2022
38.6%
Revenue Q2 2026
$11,192 M
Net Income Q2 2026
$2,817 M
Diluted EPS Q2 2026
$1.80
OCF FY2025
$12,233 M
OCF FY2024
$12,217 M
FCF FY2025
$10,664 M
FCF FY2024
$10,773 M
FCF FY2023
$7,883 M
CapEx FY2025
$1,569 M
Dividends Paid FY2025
$8,624 M
Total Assets Q2 2026
$68,271 M
Cash & Equivalents Q2 2026
$5,999 M
Total Debt Q2 2026
$49,113 M
Net Debt Q2 2026
$43,114 M
Net Debt/EBITDA
~2.5x
Current Ratio Q2 2026
0.98
Operating Margin TTM
40.0%
Net Profit Margin TTM
25.6%
ROA
14.6%
Revenue Growth YoY Q2 2026
+10.4%
Strengths
Concerns
Philip Morris International operates as the global tobacco company for markets outside the US, with headquarters in Stamford, Connecticut. The company is mid-execution on its "smoke-free transformation," pivoting from traditional cigarettes to reduced-risk products (RRPs) including IQOS heated tobacco and ZYN nicotine pouches, following the 2023 acquisition of Swedish Match.
Macro: Fed path shows 89% probability of zero rate cuts in 2026 (up 3.3pp in one week), with the 10-Year Treasury yield back above 4.7%, creating a supportive backdrop for high-payout defensive names. US recession odds are 8%, maintaining the soft-landing base case and preserving PM's defensive cash flows. However, Warsh-anchored inflation concerns and hawkish Fed rhetoric are creating cross-asset volatility and risk of multiple compression for premium-valued defensives. PM has ~70%+ non-USD revenue, making a weaker dollar a potential EPS tailwind. Consumer defensives are outperforming (MT Newswires), with broad risk-on-with-quality rotation.